Verbesserung der Klinik durch Entfernung des Soluble Fms-Like Tyrosine Kinase-1 (sFlt-1)?

Präeklampsie ist nach den Kriterien der International Society for the Study of Hypertension in Pregnancy (ISSHP) [1] eine Erkrankung während der Schwangerschaft (ca. 3–5 % der Fälle), die meist nach 20 Wochen der Gestation mit ausgeprägtem Hypertonus (> 140 mm Hgsyst/ > 90 mmHgdiast) und einer signifikanten Proteinurie (> 300 mg/Tag) einhergehen kann.

• Literatur

• 1 Tranquilli AL, Dekker G, Magee L. et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens 2014; 4: 97-104 doi: 10.1016/j.preghy.2014.02.001
• 2 Mol BW, Roberts CT, Thangaratinam S. et al. Pre-eclampsia. Lancet 2016; 387: 999-1011 doi: 10.1016/S0140–6736(15)00070–7
• 3 Sibai BM. Prevention of preeclampsia: a big disappointment. Am J Obstet Gynecol 1998; 179: 1275-1278
• 4 McCoy SBaldwinK. Pharmacotherapeutic options for the treatment of preeclampsia. Am J Health Syst Pharm 2009; 66: 337-344 doi: 10.2146/ajhp080104
• 5 Dodd JM, Turnbull D, McPhee AJ. et al. Antenatal lifestyle advice for women who are overweight or obese: LIMIT randomised trial. BMJ 2014; 348: g1285 doi: 10.1136/bmj.g1285
• 6 Maynard SE, Min JY, Merchan J. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658 doi: 10.1172/JCI17189
• 7 Chaiworapongsa T, Romero R, Kim YM. et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3-18 doi : 10.1080/14767050400028816
• 8 Verlohren S, Galindo A, Schlembach D. et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202: 161.e1-161.e11 doi: 10.1016/j.ajog.2009.09.016
• 9 Maynard S, Epstein FHKarumanchi SA. Preeclampsia and angiogenic imbalance. Annu Rev Med 2008; 59: 61-78 doi: 10.1146/annurev.med.59.110106.214058
• 10 Thadhani R. Inching towards a targeted therapy for preeclampsia. Hypertension 2010; 55: 238-240 doi: 10.1161/HYPERTENSIONAHA.109.143933
• 11 Davison JM. Dialysis, transplantation, and pregnancy. Am J Kidney Dis 1991; 17: 127-132
• 12 Martin Jr JN, Perry Jr KG, Roberts WE. et al. Plasma exchange for preeclampsia: II. Unsuccessful antepartum utilization for severe preeclampsia with or without HELLP syndrome. J Clin Apher 1994; 9: 155-161
• 13 Morelli F, Carlier P, Giannini G. et al. Hypercholesterolemia and LDL apheresis. Int J Artif Organs 2005; 28: 1025-1031
• 14 Teruel JL, Lasuncion MA, Navarro JF. et al. Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption. Metabolism 1995; 44: 929-933
• 15 Thadhani R, Kisner T, Hagmann H. et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124: 940-950 doi: 10.1161/CIRCULATIONAHA.111.034793
• 16 Thadhani R, Hagmann H, Schaarschmidt W. et al. Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. J Am Soc Nephrol 2016; 27: 903-913 doi: 10.1681/ASN.2015020157